Vourvahis, Manoli <br/><br/>
Excretion and metabolism of lersivirine (5-benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.  [electronic resource] 

 -  Drug metabolism and disposition: the biological fate of chemicals  May 2010 
 - 789-800 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-009X 
<br/><br/><label>Standard No.: </label>10.1124/dmd.109.031252  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Area Under Curve<br/>Biocatalysis<br/>Cytochrome P-450 CYP3A--metabolism<br/>Dealkylation<br/>Feces--chemistry<br/>Glucuronidase--metabolism<br/>Glucuronides--analysis<br/>Glucuronosyltransferase--metabolism<br/>Humans<br/>Hydrolysis<br/>Hydroxylation<br/>Kinetics<br/>Male<br/>Microsomes, Liver--enzymology<br/>Middle Aged<br/>Molecular Structure<br/>Nitriles--adverse effects<br/>Oxidation-Reduction<br/>Pyrazoles--adverse effects<br/>Recombinant Proteins--metabolism<br/>Reverse Transcriptase Inhibitors--adverse effects<br/>Sulfates--metabolism<br/>Tandem Mass Spectrometry